The CASP8 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line, engineered for loss-of-function interrogation of the CASP8 gene. This heterogeneous pool of edited cells provides a robust model to dissect caspase-8-dependent signaling without clonal selection bias, enabling efficient abolition of CASP8 expression across a diverse allelic spectrum.
The HT29 cell line, originally isolated from a primary colon adenocarcinoma of a 44-year-old female, is a widely used model of human intestinal epithelium and colorectal cancer. These adherent epithelial cells retain key morphological and biochemical features of enterocytic differentiation and are particularly responsive to death ligands, making them an ideal host for studying extrinsic apoptosis and necroptosis pathways.
CASP8 encodes caspase-8, an initiator caspase activated upon death receptor ligation. Engagement of Fas, TNFR1, or TRAIL receptors DR4/DR5 triggers assembly of the death-inducing signaling complex (DISC), where caspase-8 interacts with FADD and is regulated by c-FLIP. Active caspase-8 cleaves executioner caspases-3 and -7 and the pro-apoptotic BID, linking extrinsic signals to mitochondrial amplification. When caspase-8 activity is suppressed, it shifts toward necroptosis by forming complexes with RIPK1 and RIPK3, leading to MLKL phosphorylation and membrane rupture. Additionally, caspase-8 modulates NF-kappaB-mediated inflammatory signaling through interactions with TRAF2 and cIAP1/2, positioning it as a critical bifurcation point in cell death and survival.
In the context of HT29 colorectal cancer cells, CASP8 disruption offers a pathophysiologically relevant platform to examine tumor resistance to death receptor-induced apoptosis??a frequent obstacle in oncology. HT29 cells often exhibit inherent or acquired resistance to TRAIL and FasL, and this knockout model allows dissection of alternative necroptotic engagement and the contribution of FLIP isoforms. It further enables studies of NF-kappaB-driven pro-inflammatory gene expression and crosstalk between apoptotic and survival pathways, facilitating the identification of synthetic lethal interactions and novel therapeutic targets.
Common applications include Western blot analysis of caspase-8 and downstream effectors, flow cytometry-based apoptosis and necroptosis assays (Annexin V/PI and phospho-MLKL), co-immunoprecipitation of DISC components, and xenograft tumor models for in vivo drug sensitivity studies. These polyclonal cells also support RT-qPCR profiling of death receptor expression and caspase activity measurements. For additional product details or custom experimental support, please contact Ascent Research.
